Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer
The median follow-up was 17.6 months at time of interim analysis.
The median follow-up was 17.6 months at time of interim analysis.
Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.
Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.
A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.
It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.